1 exciting growth stock to buy for the long run in June

Shares of Moderna have more than doubled since mid-November. Here’s why this writer thinks it’s now a stock to buy for his portfolio.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When looking for a stock to buy, it can often be best to start with one’s own portfolio. Are there any shares in there that I’d like to add to?

There are a handful, actually. But until recently, Moderna (NASDAQ: MRNA) wasn’t one of them. That’s because sales of the firm’s only product, the Spikevax Covid vaccine, have been declining rapidly as the pandemic fades in the rear-view mirror.

In 2022, the company generated nearly $19bn in sales. This year, it’s only expecting $4bn.

Should you invest £1,000 in Vistry right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Vistry made the list?

See the 6 stocks

However, 2024 might prove to be an inflection point for this digital biotech stock. Here’s why.

Created with Highcharts 11.4.3Moderna PriceZoom1M3M6MYTD1Y5Y10YALL11 Jun 201911 Jun 2024Zoom ▾Jul '19Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '242020202020212021202220222023202320242024www.fool.co.uk

Two-product company

In late May, the company received approval for mRESVIA, a vaccine for respiratory syncytial virus (RSV). This causes mild, cold-like symptoms but can lead to serious respiratory illnesses, especially in infants and the elderly.

This was the first approved mRNA vaccine for a disease outside of Covid. But this isn’t the only RSV shot. GSK and Pfizer both had theirs approved 12 months ago.

However, Moderna’s vaccine is the only one to come in a pre-filled syringe. This compares favourably with the multi-step process of its competitors’ products.

Here’s what Moderna’s CFO James Mock said about these rival RSV jabs: “So you have to mix it and swirl it and then take a jab and measure it out. And so that is prone to error or breakage and that is cost.”

He believes that busy pharmacies and healthcare providers will buy in to its more efficient administration method. And despite being late to the party, he estimates that the firm has a good chance of capturing at least an equal share (33%) of this large market over time.

A risk to consider

Now, I should note that the firm is currently generating losses as it invests in its various programmes.

This isn’t a problem yet as it still had $12.2bn in cash and investments, as of 31 March. And the company expects to break even in 2026 through product launches and disciplined investment.

But investors will want to monitor how quickly this war chest starts to dwindle over the next couple of years. It always adds risk to the investment case when a firm is loss-making.

More positive news

Yesterday (10 June), the firm announced that its combined flu-Covid jab provoked a higher immune response when compared to separate shots (including its own Spikevax) in a late-stage trial.

If approved, this 2-in-1 jab could upend the global flu vaccine market. “This is a home run,” CEO Stéphane Bancel told Barron’s. “The whole field has been waiting for something like this.”

He estimates that the total addressable market could go up by three times compared to Covid alone.

Looking ahead, Moderna says sales from its collection of respiratory vaccines could be between $8bn-$15bn in 2027. So, the company may more than treble its sales over a three-year period.

By that point, we might also have approvals for one of its experimental mRNA cancer vaccines that are currently in phase 2 and 3 studies for several types of cancer.

There are also vaccine candidates for HIV, Zika and cytomegalovirus. The future suddenly looks very exciting. As a result, I’m going to add more shares to my portfolio for the long term.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in Moderna. The Motley Fool UK has recommended GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Investing Articles

Glencore’s share price is 53% off its 52-week highs. Is it time to consider buying?

Glencore’s share price has tanked due to concerns over an economic slowdown. Is this an amazing buying opportunity for long-term…

Read more »

Investing Articles

Forecast: in 1 year, the Marks and Spencer share price could be…

The Marks and Spencer share price has hit its highest point since 2016 after more than doubling under the new…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Down 34%, does IAG’s share price look an unmissable bargain to me now?

IAG’s share price had fallen a long way even before the latest market rout, but this may mean a bargain-basement…

Read more »

Investing Articles

Forecast: in 1 year, the HSBC share price could be…

The HSBC share price is approaching a 20-year high under its new CEO as he targets $1.5bn of savings. Here…

Read more »

Investing Articles

Forecast: in 1 year, the Barclays share price could be…

Barclays’ share price has more than tripled in the last five years as higher interest rates push up margins. But…

Read more »

Investing Articles

This FTSE 100 heavyweight’s yield is forecast to rise to 8% by 2027 and it looks 60%+ undervalued to me too!

This FTSE financial gem looks very undervalued to me and its yield is projected to rise to well over my…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

An all-time low! Have 25% car tariffs wrecked the Aston Martin share price?

The Aston Martin share price is diving into uncharted territory after Trump levied 25% duties on all cars and auto…

Read more »

Investing Articles

Forecast: in 1 year, the Tesco share price could be…

Competitive fears are driving the Tesco share price down, but has the market overreacted? Here are the latest analyst forecasts…

Read more »